The nonhomologous end joining factor Artemis suppresses multi-tissue tumor formation and prevents loss of heterozygosity

Oncogene

Volumn 26, Issue 41, 2007, Pages 6010-6020

  Woo, Y ^a,b   Wright, S M ^a   Maas, S A ^a   Alley, T L ^a   Caddle, L B ^a   Kamdar, S ^a   Affourtit, J ^a   Foreman, O ^a   Akeson, E C ^a   Shaffer, D ^a,c   Bronson, R T ^a,d,e   Morse III, H C ^f   Roopenian, D ^a,c   Mills, K D ^a  

^a JACKSON LABORATORY   (United States)

^b UNIVERSITY OF MAINE   (United States)

^c Bar Harbor BioTechnology   (United States)

^d TUFTS UNIVERSITY   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Artemis; Loss of heterozygosity; Nonhomologous end joining; p53; RS SCID

Indexed keywords

NONHOMOLOGOUS END JOINING FACTOR; PROTEIN ARTEMIS; PROTEIN P53; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; DISEASE SEVERITY; DNA REPAIR; GENE MUTATION; GLIOBLASTOMA; HETEROZYGOSITY LOSS; IMMUNE DEFICIENCY; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY;

ANIMALS; DNA REPAIR; GENES, P53; HUMANS; LOSS OF HETEROZYGOSITY; LYMPHOMA; MICE; MICE, KNOCKOUT; NEOPLASMS; NUCLEAR PROTEINS; SARCOMA, EXPERIMENTAL; SEVERE COMBINED IMMUNODEFICIENCY; TUMOR SUPPRESSOR PROTEIN P53;

MUS;

EID: 34548511545     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210430     Document Type: Article

References (37)

1. Akeson EC, Donahue LR, Beamer WG, Shultz KL, Ackert-Bicknell C, Rosen CJ et al. (2006). Chromosomal inversion discovered in C3H/HeJ mice. Genomics 87: 311-313.
2. Akeson EC, Lambert JP, Narayanswami S, Gardiner K, Bechtel LJ, Davisson MT. (2001). Ts65Dn - localization of the translocation breakpoint and trisomic gene content in a mouse model for Down syndrome. Cytogenet Cell Genet 93: 270-276.
3. Akilesh S, Shaffer DJ, Roopenian D. (2003). Customized molecular phenotyping by quantitative gene expression and pattern recognition analysis. Genome Res 13: 1719-1727.
4. Bassing CH, Suh H, Ferguson DO, Chua KF, Manis J, Eckersdorff M et al. (2003). Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors. Cell 114: 359-370.
5. Churchill GA. (2004). Using ANOVA to analyze microarray data. Biotechniques 37: 173-177.
6. de Villartay JP, Poinsignon C, de Chasseval R, Buck D, Le Guyader G, Villey I. (2003). Human and animal models of V(D)J recombination deficiency. Curr Opin Immunol 15: 592-598.
7. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS et al. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221.
8. Ege M, Ma Y, Manfras B, Kalwak K, Lu H, Lieber MR et al. (2005). Omenn syndrome due to ARTEMIS mutations. Blood 105: 4179-4186.
9. Eilers PHC, de Menezes RX. (2005). Quantile smoothing of array CGH data. Bioinformatics 21: 1146-1153.
10. Ferguson DO, Alt FW. (2001). DNA double strand break repair and chromosomal translocation: lessons from animal models. Oncogene 20: 5572-5579.
11. Hart GT, Shaffer DJ, Akilesh S, Brown AC, Moran L, Roopenian DC et al. (2004). Quantitative gene expression profiling implicates genes for susceptibility and resistance to alveolar bone loss. Infect Immun 72: 4471-4479.
12. Harvey M, McArthur MJ, Montgomery Jr CA, Butel JS, Bradley A, Donehower LA. (1993). Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet 5: 225-229.
13. Holcomb VB, Vogel H, Marple T, Kornegay RW, Hasty P. (2006). Ku80 and p53 suppress medulloblastoma that arise independent of Rag-1-induced DSBs. Oncogene 25: 7159-7165.
14. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. (2003). Summaries of Affymetrix GeneChip probe level data. Nucl Acids Res 31: e15.
15. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT et al. (1994). Tumor spectrum analysis in p53-mutant mice. Curr Biol 4: 1-7.
16. Jackson SP. (2002). Sensing and repairing DNA double-strand breaks. Carcinogenesi 23: 687-696.
17. Jasin M. (2000). Chromosome breaks and genomic instability. Cancer Invest 18: 78-86.
18. Jeggo PA, Lobrich M. (2006). Contribution of DNA repair and cell cycle checkpoint arrest to the maintenance of genomic stability. DNA Repair (Amst) 5: 1192-1198.
19. Jiang W, Ananthaswamy HN, Muller HK, Ouhtit A, Bolshakov S, Ullrich SE et al. (2001). UV irradiation augments lymphoid malignancies in mice with one functional copy of wild-type p53. PNAS 98: 9790-9795.
20. Kerr MK, Churchill GA. (2001). Experimental design for gene expression microarrays. Biostatistics 2: 183-201.
21. Lasko D, Cavenee W, Nordenskjold M. (1991). Loss of constitutional heterozygosity in human cancer. Annu Rev Genet 25: 281-314.
22. Liang L, Shao C, Deng L, Mendonca MS, Stambrook PJ, Tischfield JA. (2002). Radiation-induced genetic instability in vivo depends on p53 status. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 502: 69-80.
23. Mills KD, Ferguson DO, Alt FW. (2003). The role of DNA breaks in genomic instability and tumorigenesis. Immunol Rev 194: 77-95.
24. Moshous D, Callebaut I, de Chasseval R, Corneo B, Cavazzana-Calvo M, Le Deist F et al. (2001). Artemis, a Novel DNA Double-Strand Break Repair/V(D)J Recombination Protein, Is Mutated in Human Severe Combined Immune Deficiency. Cell 105: 177-186.
25. Moshous D, Pannetier C, Chasseval Rd R, Deist Fl F, Cavazzana-Calvo M, Romana S et al. (2003). Partial T and B lymphocyte immunodeficiency and predisposition to lymphoma in patients with hypomorphic mutations in Artemis. J Clin Invest 111: 381-387.
26. Mostoslavsky G, Fabian AJ, Rooney S, Alt FW, Mulligan RC. (2006). Complete correction of murine Artemis immunodeficiency by lentiviral vector-mediated gene transfer. Proc Natl Acad Sci U S A 103: 16406-16411.
27. Nicolas N, Moshous D, Cavazzana-Calvo M, Papadopoulo D, de Chasseval R, Le Deist F et al. (1998). A human severe combined immunodeficiency (SCID) condition with increased sensitivity to ionizing radiations and impaired V(D)J rearrangements defines a new DNA recombination/repair deficiency. J Exp Med 188: 627-634.
28. Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P et al. (2003). Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 63: 6643-6650.
29. Rooney S, Chaudhuri J, Alt FW. (2004a). The role of the non-homologous end-joining pathway in lymphocyte development. Immunol Rev 200: 115-131.
30. Rooney S, Sekiguchi J, Whitlow S, Eckersdorff M, Manis JP, Lee C et al. (2004b). Artemis and p53 cooperate to suppress oncogenic N-myc amplification in progenitor B cells. Proc Natl Acad Sci U S A 101: 2410-2415.
31. Rooney S, Sekiguchi J, Zhu C, Cheng HL, Manis J, Whitlow S et al. (2002). Leaky Scid phenotype associated with defective V(D)J coding end processing in Artemis-deficient mice. Mol Cell 10: 1379-1390.
32. Sharpless NE, Ferguson DO, O'Hagan RC, Castrillon DH, Lee C, Farazi PA et al. (2001). Impaired nonhomologous end-joining provokes soft tissue sarcomas harboring chromosomal translocations, amplifications, and deletions. Mol Cell 8: 1187-1196.
33. Stark JM, Jasin M. (2003). Extensive loss of heterozygosity is suppressed during homologous repair of chromosomal breaks. Mol Cell Biol 23: 733-743.
34. Tischfield JA, Shao C. (2003). Somatic recombination redux. Nat Genet 33: 5-6.
35. Wu H, Kerr K, Cui X, Churchill GA. (2003). The Analysis of Gene Expression Data: Methods and Software. Springer: New York.
36. Yan CT, Kaushal D, Murphy M, Zhang Y, Datta A, Chen C et al. (2006). XRCC4 suppresses medulloblastomas with recurrent translocations in p53-deficient mice. Proc Natl Acad Sci USA 103: 7378-7383.
37. Zhu C, Mills KD, Ferguson DO, Lee C, Manis J, Fleming J et al. (2002). Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations. Cell 109: 811-821.